Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chinese Academy of Medical Sciences and Peking Union Medical College PARP-1 compound A
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences and Peking Union Medical College
01
Overview
Chinese Academy of Medical Sciences and Peking Union Medical College PARP-1 compound A: sourced facts only. name: "By employing this probe to screen an in-house compound library, compound A bearing a pyrazolo[1,5-a]pyrimidine-3-carboxamide scaffold is disclosed as a structurally novel PARP-1/2 binder, which has dissociation constants of 5.6 and 7.9 μM for catPARP-1 and catPARP-2SE, respectively, in the isothermal titration calorimetry (ITC) assay." [PMID:40204633]; target: "By employing this probe to screen an in-house compound library, compound A bearing a pyrazolo[1,5-a]pyrimidine-3-carboxamide scaffold is disclosed as a structurally novel PARP-1/2 binder, which has dissociation constants of 5.6 and 7.9 μM for catPARP-1 and catPARP-2SE, respectively, in the isothermal titration calorimetry (ITC) assay." [PMID:40204633]; developer: "Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China." [PMID:40204633]
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on Chinese Academy of Medical Sciences and Peking Union Medical College PARP-1 compound A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chinese Academy of Medical Sciences and Peking Union Medical College PARP-1 compound A.